Amgen Inc. (AMGN)
| Market Cap | 142.95B |
| Revenue (ttm) | 34.13B |
| Net Income (ttm) | 5.93B |
| Shares Out | 537.71M |
| EPS (ttm) | 10.94 |
| PE Ratio | 24.30 |
| Forward PE | 12.87 |
| Dividend | $9.52 (3.58%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 3,328,795 |
| Open | 270.66 |
| Previous Close | 272.05 |
| Day's Range | 265.66 - 273.48 |
| 52-Week Range | 253.30 - 346.85 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 324.37 (+22.01%) |
| Earnings Date | May 1, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $324.37, which is an increase of 22.01% from the latest price.
News
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Lif...
Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as ...
Amgen: Waiting Patiently For A Real Catalyst
Amgen Inc.'s diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, bu...
Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1
Amgen reported strong Q1 results with a 9% YoY revenue increase and a 24% rise in operating EPS, but shares dipped due to risk-on market sentiment. Despite competitive pressures and softer EPS trends,...
Dogs Of The Dow Chase May's 'Safer' Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs cou...
Committee Movers: Eaton Corp PLC, Blackstone, Amgen, EOG Resources, Chevron and Exxon Mobile
Watch as the Investment Committee breaks down the latest market movers and shakers.
Amgen Inc. (AMGN) Q1 2025 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Comm...
Amgen quarterly profit tops Wall Street view, sales up 11%
Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales increased 11% and profit margins widened.
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025.
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the...
Amgen CEO announces $1 billion in new investments
Amgen chairman and CEO Robert Bradway unpacks the company's investments on 'The Claman Countdown.'
Amgen to expand Ohio biotech manufacturing plant
Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump administratio...
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif. , April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio man...
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry'...
Final Trades: Take-Two Interactive, Franco-Nevada, Amgen and the 10-Year Treasury
The Investment Committee give you their top stocks to watch for the second half.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Amgen: The Biotech That Knows How To Make Money
Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen achi...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Switzerland's Sandoz files antitrust lawsuit against Amgen in US
Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNew...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...